Status:

TERMINATED

Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)

Lead Sponsor:

David H. Barad

Conditions:

Premature Ovarian Failure

Eligibility:

FEMALE

21-39 years

Phase:

PHASE2

PHASE3

Brief Summary

The experimental focus of this project is on the interaction of DHEA treatment on pregnancy in women with open tubes, fertile male partners and evidence of premature ovarian failure.

Detailed Description

Recruitment: * New patients presenting for Donor egg cycles * Possible print, magazine or Radio advertisement Experimental plan: 1. Informed consent 2. Baseline studies * Antral follicle counts...

Eligibility Criteria

Inclusion

  • \>= 1 year of infertility
  • \>21 and \<40 years old
  • Normal HSG
  • Normal Semen analysis (Count \>= 20 million/ motility \> 50%/ Kruger morph \> 14%.
  • Absent menses
  • Willingness to sign informed consent for study randomization
  • Willingness to participate in 3 months of treatment.

Exclusion

  • Abnormal semen analysis
  • Abnormal HSG
  • Medical condition that would contraindicate pregnancy, ovulation induction or general anesthesia
  • Family history of significant genetic disease, or factor V leiden thrombophilia
  • Inability to present for monitoring visits
  • Inability to follow medication instruction
  • Desire to undergo other fertility treatments before completing three months of this trial

Key Trial Info

Start Date :

June 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2011

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT00948857

Start Date

June 1 2009

End Date

October 1 2011

Last Update

September 10 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Center for Human Reproduction

New York, New York, United States, 10021

Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF) | DecenTrialz